At-the-Money Calls on Sun Pharmaceutical Industries Ltd Draw 6,161 Contracts — A Signal of Immediate Directional Conviction

Options Event and Cash Market Price Action

The call options expiring on 28 Apr 2026 saw significant activity, particularly at the Rs 1,750 strike, which is almost at-the-money given the underlying price of Rs 1,728. A total of 6,161 contracts traded at this strike, generating a turnover of approximately ₹12.59 crores. This volume eclipses the open interest of 1,533 contracts at the same strike, resulting in a contracts-to-open interest ratio of roughly 4:1. Such a ratio indicates a substantial influx of fresh positions rather than mere recycling of existing ones. The stock itself outperformed its sector, gaining 7.10% on the day and touching an intraday high of Rs 1,709, signalling that the derivatives market is aligned with the cash market momentum rather than leading it. Sun Pharmaceutical Industries Ltd’s rally also outpaced the Pharmaceuticals & Biotechnology sector’s 2.32% gain and the Sensex’s 0.59% rise, underscoring the stock-specific strength behind this options activity.

Strike Price and Moneyness Analysis

The Rs 1,750 strike calls are effectively at-the-money, given the underlying price of Rs 1,728. This proximity means these options are highly sensitive to immediate price movements, with gamma exposure maximised. Traders engaging at this strike are signalling conviction in near-term directional movement rather than speculative bets on distant price targets. In contrast, other active strikes such as Rs 1,740 and Rs 1,690 are slightly in-the-money, suggesting some hedging or deeper conviction plays, while strikes like Rs 1,750 and Rs 1,740 being so close to the current price emphasise a focus on short-term price action. Sun Pharmaceutical Industries Ltd’s options flow thus reveals a nuanced positioning strategy, blending immediate directional bets with some hedging at slightly in-the-money levels. What does this concentration of near-the-money activity imply for the stock’s short-term trajectory?

Open Interest and Contracts Analysis

Examining open interest alongside traded contracts provides insight into the nature of the positioning. The Rs 1,750 strike’s open interest stands at 1,533 contracts, while 6,161 contracts traded on the day. This elevated contracts-to-OI ratio of approximately 4:1 strongly suggests fresh money entering the market rather than existing holders adjusting positions. Similarly, the Rs 1,740 strike saw 5,398 contracts traded against an open interest of 1,757, reinforcing the theme of new directional bets. The Rs 1,690 strike, slightly in-the-money, recorded 6,631 contracts traded with an open interest of 994, again indicating fresh activity. This pattern of high turnover relative to open interest across multiple strikes points to a broad-based surge in call buying, not confined to a single strike or expiry. The expiry date of 28 Apr 2026 is imminent, adding urgency to these bets and highlighting a short-term focus among options traders. Sun Pharmaceutical Industries Ltd’s options market is thus signalling a concentrated, near-term directional conviction.

Cash Market Context and Moving Averages

The stock’s price action confirms the bullish positioning evident in the options market. After a strong 7.10% gain on 27 Apr 2026, Sun Pharmaceutical Industries Ltd is trading above its 5-day moving average but remains below its 20-day, 50-day, 100-day, and 200-day moving averages. This suggests that while short-term momentum is building, the stock has yet to break through longer-term resistance levels. The weighted average price of traded shares skewed closer to the day’s low, indicating some profit-taking or cautious buying despite the rally. The alignment of rising call option activity with a strong cash market rally points to a coherent directional view, but the stock’s position relative to key moving averages invites the question: is this momentum sustainable or a prelude to consolidation?

Delivery Volume and Market Participation

Delivery volumes provide an additional layer of confirmation for the options activity. On 24 Apr 2026, delivery volume surged to 63.23 lakh shares, a 234% increase against the 5-day average, signalling strong investor participation in the cash market ahead of the options expiry. This elevated delivery volume suggests that the rally is supported by genuine buying interest rather than speculative short-term trading alone. The combination of rising delivery volumes and heavy call option activity at near-the-money strikes reinforces the interpretation of a concerted directional bet rather than isolated speculative positioning. how will this interplay between cash market participation and derivatives positioning evolve as expiry approaches?

Key Data at a Glance

Conclusion: What the Options and Cash Data Collectively Signal

The surge in call option contracts at the Rs 1,750 strike, combined with a contracts-to-open interest ratio of 4:1, points to a strong influx of fresh bullish bets on Sun Pharmaceutical Industries Ltd. The near-the-money strike price selection reveals a focus on immediate directional movement rather than speculative distant targets. This is corroborated by the stock’s 7.10% gain on the day and elevated delivery volumes, which confirm genuine cash market participation. However, the stock remains below key longer-term moving averages, suggesting that while short-term momentum is building, the broader trend has yet to decisively shift. The options market and cash market are aligned in signalling a near-term bullish stance, but is this a momentum play worth joining or has the easy move already happened?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →